News

Selumetinib was assessed in combination with docetaxel chemotherapy as a second-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The phase

Scintilla's lead program is resiniferatoxin ("RTX") for the treatment of intractable cancer pain. SCILEX, based in Malvern, PA, is engaged in the development and commercialization of products focused

Known as INNO2VATE, the program consists of two studies designed to evaluate vadadustat in patients with anemia related to chronic kidney disease who are undergoing dialysis. Akebia's ongoing

The milestone, which triggered an undisclosed payment from Astellas, demonstrated that selective modulation of the Unfolded Protein Response (UPR) pathway in vitro is potentially an effective disease-modifying approach

The licensing, development and commercialization agreement is intended at rapidly advancing Pracinostat into phase III clinical development and expanding the treatment into further indications that include high-risk myelodysplastic

Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology indications. Lantern Pharma is a Precision Oncology Medicine company

This collaboration marks the first time ScinoPharm will collaborate with an external partner, CVie, from a discovery (pre-IND) perspective. According to the agreement, the primary goal of the

The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration (FDA) voted 18 to 1 to

The binding domains were developed under a collaboration agreement between Eureka Therapeutics and MSK. The parties expect the BCMA CAR to enter human testing as early as 1H2017.